Published in J Hepatol on January 15, 2013
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int (2015) 1.92
Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology (2015) 1.44
Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program. J Gen Intern Med (2015) 0.90
Use of Population-Based Data to Demonstrate How Waitlist-Based Metrics Overestimate Geographic Disparities in Access to Liver Transplant Care. Am J Transplant (2016) 0.87
Hepatitis prevention project in the Korean American community in Killeen, Texas. Proc (Bayl Univ Med Cent) (2015) 0.81
Community-based hepatitis B screening: what works? Hepatol Int (2014) 0.80
Simultaneous Human Immunodeficiency Virus-Hepatitis B-Hepatitis C Point-of-Care Tests Improve Outcomes in Linkage-to-Care: Results of a Randomized Control Trial in Persons Without Healthcare Coverage. Open Forum Infect Dis (2015) 0.75
Current state of and needs for hepatitis B screening: results of a large screening study in a low-prevalent, metropolitan region. PLoS One (2014) 0.75
Testing and Linking Foreign-Born People with Chronic Hepatitis B Virus Infection to Care at Nine U.S. Programs, 2012-2014. Public Health Rep (2016) 0.75
Current Issues Involving Screening for Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y) (2015) 0.75
A Novel Collaborative Community-Based Hepatitis B Screening and Linkage to Care Program for African Immigrants. Clin Infect Dis (2016) 0.75
Characteristics of Asian American, Native Hawaiian, and Pacific Islander community health worker programs: a systematic review. J Health Care Poor Underserved (2015) 0.75
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol (2008) 7.38
Pathogenesis of liver fibrosis. Annu Rev Pathol (2011) 5.27
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97
Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol (2011) 2.82
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology (2004) 2.54
Activation of hepatic stellate cells--a key issue in liver fibrosis. Front Biosci (2002) 2.49
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology (2004) 2.28
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med (2013) 2.25
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol (2007) 2.16
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol (2004) 2.12
Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology (2012) 2.11
Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology (2002) 2.10
The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology (2008) 2.04
A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res (2005) 2.02
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98
Regulation of hepatic stellate cell activation and growth by transcription factor myocyte enhancer factor 2. Gastroenterology (2004) 1.94
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol (2006) 1.92
Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology (2012) 1.91
Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl (2012) 1.90
Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology (2007) 1.88
Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol (2006) 1.86
Scraping fibrosis: expressway to the core of fibrosis. Nat Med (2011) 1.82
Functions of autophagy in normal and diseased liver. Autophagy (2013) 1.81
Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. Br J Pharmacol (2006) 1.79
Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis (2008) 1.78
Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology (2013) 1.78
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77
Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med (2002) 1.76
Hepatic stellate cells and liver fibrosis. Compr Physiol (2013) 1.75
Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology (2009) 1.72
Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology (2006) 1.71
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology (2010) 1.70
Barriers to screening for hepatitis B virus infection in Asian Americans. Dig Dis Sci (2011) 1.69
Hepatic fibrosis. Curr Opin Gastroenterol (2009) 1.67
Pneumatosis intestinalis in adults: management, surgical indications, and risk factors for mortality. J Gastrointest Surg (2007) 1.66
Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res (2005) 1.65
Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology (2014) 1.62
Impact of increased syringe access: preliminary findings on injection drug user syringe source, disposal, and pharmacy sales in Harlem, New York. J Am Pharm Assoc (Wash) (2002) 1.62
The movement of aquatic mercury through terrestrial food webs. Science (2008) 1.61
Experimental models of hepatocellular carcinoma. J Hepatol (2008) 1.61
Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology (2004) 1.59
Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res (2004) 1.57
Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. J Hepatol (2013) 1.52
Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res (2006) 1.51
Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. J Biol Chem (2001) 1.51
Hepatic fibrosis--role of hepatic stellate cell activation. MedGenMed (2002) 1.51
Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. Hepatology (2003) 1.48
Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology (2009) 1.47
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol (2004) 1.47
Krüppel-like factor-6 promotes preadipocyte differentiation through histone deacetylase 3-dependent repression of DLK1. J Biol Chem (2005) 1.46
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res (2012) 1.44
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver Int (2013) 1.43
Cytochrome P450 2E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells. J Biol Chem (2002) 1.43
The management of chronic hepatitis B in Asian Americans. Dig Dis Sci (2011) 1.42
Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species. Hepatology (2002) 1.40
Developmental regulation of yolk sac hematopoiesis by Kruppel-like factor 6. Blood (2005) 1.39
More study needed on morning erections and erectile dysfunction. Am J Med (2009) 1.39
Acute HIV seroconversion in a patient receiving pegylated interferon for treatment of hepatitis C. AIDS Read (2003) 1.38
Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfected with HIV and HCV genotype 1. AIDS Read (2006) 1.38
Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. J Biol Chem (2002) 1.38
KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J Clin Invest (2008) 1.36
Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol (2011) 1.34
Lhx2-/- mice develop liver fibrosis. Proc Natl Acad Sci U S A (2004) 1.33
Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther (2007) 1.33
Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats. Gut (2006) 1.31
Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis. Hepatology (2008) 1.31
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology (2004) 1.30
Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol (2008) 1.29
BMP-7 opposes TGF-beta1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. Am J Physiol Lung Cell Mol Physiol (2005) 1.28
A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice. Hepatology (2013) 1.27
Hepatic fibrogenesis. Semin Liver Dis (2007) 1.27
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol (2012) 1.26
Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology (2009) 1.24
Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression. Hepatology (2012) 1.24
Acute liver failure is associated with elevated liver stiffness and hepatic stellate cell activation. Hepatology (2010) 1.22
Stellate cells: a moving target in hepatic fibrogenesis. Hepatology (2004) 1.22
Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression. J Hepatol (2005) 1.21
Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology (2008) 1.21
Regulation of Kruppel-like factor 6 tumor suppressor activity by acetylation. Cancer Res (2005) 1.20
Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology (2006) 1.20
Cellular basis of hepatic fibrosis and its role in inflammation and cancer. Front Biosci (Schol Ed) (2013) 1.19
The RING finger protein, RNF8, interacts with retinoid X receptor alpha and enhances its transcription-stimulating activity. J Biol Chem (2004) 1.18
Reduced nicotinamide adenine dinucleotide phosphate oxidase 2 plays a key role in stellate cell activation and liver fibrogenesis in vivo. Gastroenterology (2010) 1.18
Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. Int J Cancer (2007) 1.17
Advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol (2008) 1.17